| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC7904 | CTX0294885 Featured | CTX-0294885 is a novel broad-spectrum kinase inhibitor. |
|
| DC20934 | CU239 | CU239 is a novel non-retinoid RPE65 inhibitor that selectively inhibits isomerase activity of RPE65 with IC50 of 6 uM. |
|
| DC20952 | CU-3 | CU-3 (DGKα inhibitor CU-3) is a is a novel potent, selective diacylglycerol kinase α (DGKα) inhibitor with IC50 of 0.6 uM, targets the catalytic region, but not the regulatory region. |
|
| DC10771 | CU-CPT-8m Featured | CU-CPT-8m is a nolve TLR8 inhibitor. |
|
| DC10769 | CU-CPT-9b Featured | CU-CPT9b is an antagonist of toll-like receptor 8 (TLR8; Kd = 21 nM). |
|
| DC10770 | CU-CPT-9a Featured | CU-CPT9a is an antagonist of toll-like receptor 8 (TLR8). It inhibits activation of NF-κB induced by the TLR8 agonist R-848 in TLR8-overexpressing HEK-Blue cells (IC50 = 0.5 nM). CU-CPT9a reverses R-848-induced increases in NF-κB p65, IRAK-4, and TRAF3 protein levels in HEK-Blue cells. |
|
| DC9282 | cucurbitacin B Featured | Cucurbitacin B, an oxygenated tetracyclic triterpenoid compound extracted from Cucurbitaceae plant species, is a long-term anticancer agent by disruption of microtubule polymerization. |
|
| DC23035 | Curcurbitacin IIa Featured | Cucurbitacin IIa has anti-cancer, anti-bacterial, and anti-inflammatory effects, it can induce apoptosis and enhance autophagy; it also can disrupt the actin cytoskeleton and direct the cell to undergo PARP-mediated apoptosis through the inhibition of sur |
|
| DC7544 | CUDC-101 Featured | CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
|
| DC23897 | CUR-61414 | CUR-61414 is a small molecule Hedgehog (Hh) inhibitor that can block elevated Hh signaling activity resulting from oncogenic mutations in Patched-1, binds directly with Smoothened (Ki=44 nM). |
|
| DC23726 | Cuspin-1 | Cuspin-1 is a small molecule upregulator of SMN (Survival of Motor Neuron protein) with EC50 of 18 uM. |
|
| DC9699 | CVM-1118(CVM1118) Featured | CVM-1118(CVM1118) has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM). |
|
| DC7391 | CVT-10216 Featured | CVT-10216 is a potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) (IC50 values are 29 and 1300 nM for ALDH2 and ALDH1, respectively). |
|
| DC12291 | CVT-12012 | CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively. |
|
| DC9306 | CVT-313(NG-26) Featured | CVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1). |
|
| DC7392 | CW069 Featured | CW-069 is a novel and allosteric inhibitor of the microtubule motor protein HSET with IC50 value of 75 ± 20 μM; shows statistically significant selectivity over KSP. |
|
| DC9278 | CWHM-12 Featured | CWHM-12 a novel small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8; less potency on αvβ5(IC50=61 nM) and on inhibition on αIIbβ3/α2β1/α10β1. |
|
| DC20936 | CWP-232228 | CWP-232228 is a highly potent small-molecule Wnt/β-catenin signaling inhibitor that targets the β-catenin/Tcf4 interaction in the nucleus. |
|
| DC11980 | CX 4338 | CX 4338 (CX4338, CX-4338) is a potent, selective CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with IC50 of 6.3 uM. |
|
| DC7111 | CX-4945 (Silmitasertib) Featured | CX-4945 (Silmitasertib) is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively. |
|
| DC23942 | CX-4945 sodium salt(Silmitasertib) Featured | CX-4945 Sodium Salt is a water soluble CX-4945 (GLXC-04060), First-in-class Casein kinase 2 (CK2) inhibitor, sequentially attenuating the proteins in PI3K/Akt and MAPK pathways. |
|
| DC24074 | CX-546 Featured | CX546 is an AMPA receptor potentiator and GluR activator, binds specifically to the agonist bound non-desensitized receptor. |
|
| DC7810 | CX-5461 Featured | CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA, has no effect on Pol II, and possesses 250-to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. |
|
| DC23632 | CX-614 | CX-614 is a positive allosteric modulator of AMPA receptors, shows neuroprotective effects for treatment of Parkinson's disease and Alzheimer's disease. |
|
| DC7153 | CX6258 Featured | CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity. |
|
| DC10203 | CXCR2-IN-1 | CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonists with a pIC50 of 9.3. |
|
| DC23524 | CXCR2-IN-68 | CXCR2-IN-68 is a potent, selective, brain penetrant, and orally bioavailable CXCR2 antagonist with pIC50 of 9.0, displays 730-fold selectivity over CXCR1 and >1,900-fold selectivity over all other chemokine receptors. |
|
| DC9925 | CXD101(AZD-9468) Featured | CXD101(AZD-9468) is a novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. |
|
| DC20349 | CXL017 | CXL017 is a small molecule that has selective cytotoxicity toward MDR cancer cell lines in vitro, through inhibition of the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) with IC50 of 15 uM. |
|
| DC10620 | CY-09 Featured | CY-09 is an NLRP3 inhibitor. |
|
